My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Evolocumab Biosimilar, PCSK9 Monoclonal Antibody

Evolocumab Biosimilar, PCSK9 Monoclonal Antibody

Proprotein Convertase Subtilisin/Kexin Type 9

Catalog No. Product Name Size List Price (US$) Quantity
C105P Evolocumab Biosimilar, Human PCSK9 Monoclonal Antibody 1 mg 175.00
C105P Evolocumab Biosimilar, Human PCSK9 Monoclonal Antibody 5 mg 600.00
C105P Evolocumab Biosimilar, Human PCSK9 Monoclonal Antibody 20 mg 1200.00
C105P.05 Evolocumab Biosimilar, Endotoxin 0.05 EU/mg 5 mg 900.00
C105P.05 Evolocumab Biosimilar, Endotoxin 0.05 EU/mg 20 mg 1800.00
Description

C105P: Evolocumab Biosimilar, PCSK9 Monoclonal Antibody

Recombinant fully human IgG2 Monoclonal Antibody.
Isotype: Human IgG2 lambda.
Source: The anti-PCSK9 monoclonal antibody evolocumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The monoclonal antibody evolocumab biosimilar specifically binds to the human PCSK9.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by evolocumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The monoclonal antibody evolocumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is evolocumab biosimilar research grade? Evolocumab (trade name Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. The PCSK9 protein targets LDL receptors for degradation. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in turn preventing PCSK9-mediated LDLR degradation and permitting the LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Evolocumab biosimilar uses the same protein sequences as the therapeutic antibody evolocumab.

Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)

Related Links

See our Privacy Policy